Where We Are
What We Do
Industries We Serve
Pharmaceuticals
Global Regulatory Partners Inc. (GRP) provides hands-on regulatory affairs services to pharmaceutical, biologic and generic drug companies. The GRP regulatory team has many years of experience helping companies develop and register their products in different markets in compliance with local regulations, in record time, and with minimal risk. Services provided by GRP include, but are not limited to, Regulatory Intelligence, Regulatory Strategy, Consultation Meetings with Health Authorities, Regulatory Operations, Clinical Trial Operations, Medical Writing and Publishing, Product Registration, and Product Life-Cycle Management.,
Medical Devices
GRP provides hands-on regulatory affairs services to pharmaceutical, biologic and generic drug companies. The GRP regulatory team has many years of experience helping companies develop and register their products in different markets in compliance with local regulations, in record time, and with minimal risk. Services provided by GRP include, but are not limited to, Regulatory Intelligence, Regulatory Strategy, Consultation Meetings with Health Authorities, Regulatory Operations, Clinical Trial Operations, Medical Writing and Publishing, Product Registration, and Product Life-Cycle Management.
Cosmetics
GRP offers a comprehensive range of services for Cosmetics and Personal Care Products (PCP) to cosmetic and nutraceutical companies. GRP’s team of professionals ensure that your products meet the latest safety regulations applicable to your product before being commercialized and used by consumers. GRP cosmetics services include formulation review and assessment, labeling review, product registration (as needed) and post-marketing surveillance.
Nutraceuticals
The global Nutraceutical and Dietary Supplement markets are a rapidly growing due to changing lifestyles, increasing health concerns of consumers and a growing awareness for the need to consume healthful and nutritional foods and food supplements. GRP has a team of experts who help Nutraceutical and Dietary Supplement companies worldwide to register and commercialize their products in compliance with local regulations. GRP services include, but not limited to the review of product formulations, excipient content, nutrient content, labelling, artwork, and health claims.
Pharmacovigilance
GRP provides pharmacovigilance services to Pharmaceutical, Biologic, Medical Device, Nutraceutical and Cosmetic companies worldwide. The GRP pharmacovigilance team members have long standing industry experience and consistently deliver high quality and compliant pharmacovigilance services. These help companies optimize their products’ risk-benefit profile and help improve the safety of patients and consumers.
Quality
The GRP Quality Team has the required skills, experience and certifications to assist pharmaceutical and medical device companies attain and remain in compliance with the required quality standards. The GRP Quality Team helps companies develop or review their quality standard operating procedures (SOPs), implement and maintain an appropriate quality management system (QMS), and manage compliance with applicable GMP, ISO 13485, GCP, CGTP and other quality standards through their products’ life-cycle. GRP has Certified Quality Auditors who can help you prepare for FDA inspections and prepare prompt responses to inspectional observations.
About GRP
Who We Are
We are a consulting company that provides a full spectrum of tailored Regulatory Affairs, Clinical, Quality and Pharmacovigilance Services to pharmaceutical, medical device, cosmetic, and Nutraceutical companies worldwide.
Our main focus is to provide our life science clients with tailored services that meet their business needs, fit their budget and support their strategic growth globally.
From our Blog
Brazil’s Anvisa Announces New Medical Device Regulations
On September 18,2020 Brazil’s Anvisa published the RDC no. 423/2020 which deals with the extinction of the registration and migration of medical devices of risk class II to the notification regime.
China’s CDE publishes draft for a list of Drugs exempt from BE Studies
China’s CDE publishes draft listing 117 drugs that will be exempt from BE studies.
Brazil’s Anvisa establishes New Standards on label warnings and formulas
Brazil’s Anvisa new standards require companies to warn about formula changes in products subject to health surveillance.
China’s NMPA Addresses Common Period Risk Evaluation Report (PRER) Issues
China’s NMPA updates and address some common issues faced by the Marketing Authorization Holders to submit PRER report.
China’s NMPA resolves issues regarding current administration on drug distribution
NMPA announces a new revised Drug Administration Law of the People’s Republic of China effective since Dec 1, 2019.
Mexico’s COFEPRIS establishes new electronic Appointment System
From September,1st 2020 COFEPRIS establishes the request for appointments will be via the internet and face-to-face attention in the CIS for the entry of priority formalities.
